Intrasense SA (ALINS) AI Stock Analysis

• Market Cap: €15.86M
• Dividend Yield: N/A
• Average Volume (3M): 17.32K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.42
• Revenue Growth: -32.04%
• EPS Growth: -19.23%
• Country: FR
• Employees: 76
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.07
• Shares Outstanding: 52,716,263
• 10 Day Avg. Volume: 18,798
• 30 Day Avg. Volume: 17,320
• PEG Ratio: -0.02
• Price to Book (P/B): 5.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: €0.50 ▲(66.67%Upside)

The overall score of 42 reflects Intrasense SA's major financial struggles and negative valuation metrics. The technical analysis provides a slight positive offset, but the lack of earnings call data and corporate events leaves broader strategic uncertainties unaddressed. Significant improvements in financial performance are crucial for a positive outlook.

Intrasense SA Business Overview & Revenue Model

Company Description

Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams. The company was incorporated in 2004 and is headquartered in Montpellier, France.

How the Company Makes Money

Intrasense SA generates revenue primarily through the sale and licensing of its Myrian software platform to hospitals, clinics, and diagnostic centers worldwide. The company offers various modules and customization options, allowing clients to tailor the software to their specific needs, which generates additional revenue streams. Intrasense also engages in service contracts, maintenance agreements, and training services associated with its software offerings. Partnerships with medical equipment manufacturers and distributors further enhance its market reach and revenue potential. The company's earnings are influenced by the adoption of digital imaging technologies in healthcare and the continuous need for innovative diagnostic tools.

Intrasense SA Financial Statement Overview

Summary

Intrasense SA is experiencing declining revenues, consistent net losses, and a weak balance sheet. Negative margins and cash flow highlight operational inefficiencies and financial instability. High leverage and low equity position further increase financial risk.

Income Statement

Intrasense SA has been experiencing declining revenue with a negative trend in profitability. The gross profit margin is negative, indicating cost of goods sold exceeds revenue. Net profit margin is also negative, reflecting consistent net losses. There is a concerning decline in revenue over the years, with significant operating losses as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio, indicating reliance on debt financing. The equity ratio is low, reflecting potential financial instability. Return on equity is negative, indicating that shareholders are not seeing returns on their investment. These factors suggest financial vulnerability and limited equity to cover liabilities.

Cash Flow

Intrasense SA reports negative operating cash flow and free cash flow, highlighting cash burn and operational challenges. The company is not generating sufficient cash from operations to cover expenses, and free cash flow is declining, indicating worsening cash position over time. The operating cash flow to net income ratio is negative, suggesting poor cash earnings quality.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.25M	3.31M	3.79M	4.19M	3.44M
Gross Profit	-3.81M	-885.00K	-1.15M	-1.05M	-454.00K
EBITDA	-4.60M	-2.68M	-2.73M	-611.00K	-214.00K
Net Income	-5.66M	-3.58M	-3.42M	-1.20M	-704.00K
Balance Sheet
Total Assets	7.68M	10.45M	6.51M	8.77M	6.36M
Cash, Cash Equivalents and Short-Term Investments	930.00K	4.55M	1.41M	4.76M	2.59M
Total Debt	1.41M	1.49M	2.06M	1.93M	2.26M
Total Liabilities	6.03M	3.17M	4.50M	3.78M	4.21M
Stockholders Equity	1.65M	7.29M	2.01M	4.99M	2.15M
Cash Flow
Free Cash Flow	-5.94M	-4.97M	-3.48M	-1.50M	-1.08M
Operating Cash Flow	-3.73M	-3.05M	-2.00M	-948.00K	-481.00K
Investing Cash Flow	-2.21M	-1.93M	-1.49M	-555.00K	-551.00K
Financing Cash Flow	2.33M	8.10M	137.00K	3.66M	2.75M

Intrasense SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALINS, the sentiment is Positive. The current price of 0.3 is below the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.29, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.56 is Neutral, neither overbought nor oversold. The STOCH value of 25.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALINS.

Intrasense SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	46 Neutral	C$190.36M	-4.25	-8.56%	3.09%	13.53%	-1.76%
ALAMA	44 Neutral	€12.94M	―		―	-17.36%	8.61%
ALINS	42 Neutral	€15.86M	―	-126.47%	―	-32.04%	-19.23%
DMS1		€25.96M	―	-22.84%	―	―	―
9W8		€21.51M	―	-16.43%	―	―	―
61R		€11.36M	―		―	―	―
4ZG		€31.33M	―		―	―	―